Literature DB >> 2599903

Radiotherapy for anal cancer: experience from 1979-1987.

L L Hughes1, T A Rich, L Delclos, J A Ajani, R G Martin.   

Abstract

Seventy patients with squamous cell carcinoma or cloacogenic carcinoma of the anus treated from 1979-1987 were reviewed. Five groups were analyzed: (a) local excision (LE) with postoperative radiotherapy (n = 9); (b) abdominoperineal resection (APR) with either pre- or postoperative radiotherapy (n = 22); (c) definitive radiotherapy alone (n = 8); (d) radiotherapy with continuous 5-Fluorouracil (5-FU) infusion (chemoradiation) (n = 25); and (e) patients treated for recurrent disease (n = 6). Abdomino-perineal resection and radiotherapy resulted in an actuarial local control (LC) rate of 90% and an overall 5-year survival rate of 77% (median follow-up, 48 months). All patients in Group 1 and 5/8 patients in Group 3 had locally controlled disease and were disease-free. The chemoradiation protocol resulted in a complete clinical response rate of 75% (18/24, one patient died during treatment) assessed 4-6 weeks after treatment. The colostomy-free local control rate with chemoradiation is 67% (16/24). Local control was 50% for all stages receiving 45-49 Gy and 90% for those patients receiving greater than or equal to 55 Gy but was not correlated with total 5-FU dose. Abdomino-perineal resection was performed to salvage six patients with persistent disease and two with recurrent disease, resulting in an overall local control rate of 92% (22/24). The actuarial survival was 96% (median follow-up, 14 months; range, 1-30). The acute complications of radiotherapy included diarrhea and perineal skin reactions that were increased by 5-FU infusion. However, diarrhea can be ameliorated by a modified treatment technique that reduces irradiation to the small intestine. For the entire patient group, minor late complications occurred in 23%, and major complications occurred in 9%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2599903     DOI: 10.1016/0360-3016(89)90520-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

1.  Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292).

Authors:  A Bapsi Chakravarthy; Paul J Catalano; James A Martenson; Joshua K Mondschein; Henry Wagner; Edward G Mansour; Mark S Talamonti; Al Bowen Benson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-20       Impact factor: 7.038

2.  [Anal HPV infections].

Authors:  Felix Aigner; Friedrich Conrad; Andreas Widschwendter; Robert Zangerle; Bettina Zelger; Alfred Haidenberger; Sebastian Roka; Kurt Heim; Reinhard Höpfl; Martin Klimpfinger; Yves Marcus Rigler; Hugo Bonatti; Johann Pfeifer; Andrea Maier; Reinhard Kirnbauer; Andreas Salat
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 3.  Advances in the Management of Anal Cancer.

Authors:  Diana R Julie; Karyn A Goodman
Journal:  Curr Oncol Rep       Date:  2016-03       Impact factor: 5.075

Review 4.  [Prevention and therapy of acute radiation-related morbidity of the skin and mucosa. II, Recommendations of the literature].

Authors:  J S Zimmermann; P Niehoff; R Wilhelm; R Schneider; G Kovács; B Kimmig
Journal:  Strahlenther Onkol       Date:  1998-04       Impact factor: 3.621

Review 5.  [The use of sucralfate in radiation oncology].

Authors:  C Belka; W Hoffmann; F Paulsen; M Barnberg
Journal:  Strahlenther Onkol       Date:  1997-05       Impact factor: 3.621

6.  Radiochemotherapy in Anal Cancer: cCR, clinical outcomes and quality of life using two different treatment schedules.

Authors:  Sara Di Santo; Marianna Trignani; Matteo Neri; Angelo Milano; Paolo Innocenti; Maria Taraborrelli; Antonietta Augurio; Annamaria Vinciguerra; Monica Di Tommaso; Lucia Anna Ursini; Angelo Di Pilla; Marta Di Nicola; Domenico Genovesi
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-22

7.  Radiotherapy with or without chemotherapy in the treatment of anal cancer: 20-year experience from a single institute.

Authors:  K Fakhrian; T Sauer; S Klemm; C Bayer; B Haller; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2012-11-15       Impact factor: 3.621

8.  Epidermoid carcinoma of the anal canal.

Authors:  Bruce W Robb; Matthew G Mutch
Journal:  Clin Colon Rectal Surg       Date:  2006-05

9.  Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy.

Authors:  W E Longo; A M Vernava; T P Wade; M A Coplin; K S Virgo; F E Johnson
Journal:  Ann Surg       Date:  1994-07       Impact factor: 12.969

10.  A fast radiotherapy paradigm for anal cancer with volumetric modulated arc therapy (VMAT).

Authors:  Florian Stieler; Dirk Wolff; Frank Lohr; Volker Steil; Yasser Abo-Madyan; Friedlieb Lorenz; Frederik Wenz; Sabine Mai
Journal:  Radiat Oncol       Date:  2009-10-25       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.